Abstract

Metabolic dysfunction–associated steatohepatitis (MASH) is a severe form of liver disease that poses a global health threat because of its potential to progress to advanced fibrosis, leading to cirrhosis and liver cancer. Recent advances in single-cell methodologies, refined disease models, and genetic and epigenetic insights have provided a nuanced understanding of MASH fibrogenesis, with substantial cellular heterogeneity in MASH livers providing potentially targetable cell-cell interactions and behavior. Unlike fibrogenesis, mechanisms underlying fibrosis regression in MASH are still inadequately understood, although antifibrotic targets have been recently identified. A refined antifibrotic treatment framework could lead to noninvasive assessment and targeted therapies that preserve hepatocellular function and restore the liver’s architectural integrity.

Original languageEnglish
Article numbereadi0759
JournalScience Translational Medicine
Volume15
Issue number716
DOIs
StatePublished - 4 Oct 2023

Fingerprint

Dive into the research topics of 'Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)'. Together they form a unique fingerprint.

Cite this